NASDAQ:TYME Tyme Technologies (TYME) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free TYME Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.29▼$0.3250-Day Range$0.24▼$0.3552-Week Range$0.22▼$1.14Volume2.68 million shsAverage Volume1.01 million shsMarket Capitalization$53.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Tyme Technologies alerts: Email Address Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here About Tyme Technologies Stock (NASDAQ:TYME)Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey.Read More Ad Crypto Swap ProfitsHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.>> Register right here TYME Stock News HeadlinesApril 19, 2024 | yahoo.com50 Mother’s Day Gifts on Amazon She'll Never Guess You Bought Last-MinuteApril 16, 2024 | yahoo.comTop teen chef: SST student and Vino e Vivo cook Orion Raczek wins big SkillsUSA contestApril 24, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.April 16, 2024 | msn.comIqaluit's Toonik Tyme wraps up with race to Kimmirut and backApril 13, 2024 | msn.comThyme Companion Planting Guide [What to Plant with Thyme]April 3, 2024 | ca.news.yahoo.comHow your tax returns could be affected by CRA's bare trust debacleApril 2, 2024 | msn.com25 Pun-Tastic Creations From This Artist’s SketchpadApril 1, 2024 | msn.comNinja Foodi Beef StewApril 24, 2024 | Insiders Exposed (Ad)The Hard Truth About Investing For RetirementHere’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.March 23, 2024 | msn.com7 great Google Gemini AI prompts to try this weekendMarch 19, 2024 | markets.businessinsider.comEden Green Launches Flagship Herb ProgramMarch 19, 2024 | finance.yahoo.comVertical farm to provide fresh herbs to retailers in Texas, OklahomaMarch 15, 2024 | yahoo.com5 Kitchen Must-Haves For Your DIY LifestyleMarch 12, 2024 | msn.com8 Simple Habits of People Who Have a Thriving, Bird-Friendly BackyardMarch 11, 2024 | msn.comClos Apalta: fabulous wines from ChileFebruary 25, 2024 | msn.com‘Real music by real musicians’: New recording studio in Vandalia Tower aims to build sustainable music careers for youth of colorFebruary 24, 2024 | msn.comGokongwei-backed digital bank to launch ATM servicesFebruary 22, 2024 | news.yahoo.comPublic invited to BSU Sings! Day concert set for March 13February 22, 2024 | yahoo.comThe 8 Best New Colognes of 2024 (So Far)February 20, 2024 | msn.com“What is An Item That Everyone Misuses But The Makers Pretend They Don’t Know?” (32 Answers)February 16, 2024 | cbsnews.comWomen's HealthFebruary 3, 2024 | msn.comNinja Foodi Lamb ChopsFebruary 1, 2024 | msn.comThyme: Nutrition Professionals Guide You On Optimal Intake, Portions, And Health BenefitsJanuary 31, 2024 | msn.comHow to use essential oilsJanuary 31, 2024 | yahoo.comDespite glimmers of profit, most African neobanks remain in the redJanuary 24, 2024 | msn.comKeyrus unlocks powerful dynamic data visualisation for GoTyme BankJanuary 20, 2024 | msn.comCan You Put a Whole Chicken in an Air FryerSee More Headlines Receive TYME Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyme Technologies and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/24/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TYME CUSIPN/A CIK1537917 Webwww.tymeinc.com Phone(212) 461-2315FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,630,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-28.30% Return on Assets-26.21% Debt Debt-to-Equity RatioN/A Current Ratio14.06 Quick Ratio14.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.47 per share Price / Book0.66Miscellaneous Outstanding Shares172,207,000Free Float143,104,000Market Cap$53.50 million OptionableOptionable Beta0.93 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard Cunningham (Age 51)CEO & Director Comp: $789.9kMr. Steven E. Hoffman (Age 59)Co-Founder & Director Comp: $2.6MMr. Frank L. Porfido (Age 58)Chief Financial Officer Comp: $488.2kMr. James Biehl J.D. (Age 58)Chief Legal Officer & Sec. Comp: $635.89kDr. Jonathan M. Eckard (Age 48)Chief Bus. Officer Dr. Jan Marie-Albert Van Tornout M.D. (Age 66)M.Sc., Acting Chief Medical Officer More ExecutivesKey CompetitorsEledon PharmaceuticalsNASDAQ:ELDNHomology MedicinesNASDAQ:FIXXGain TherapeuticsNASDAQ:GANXCheckpoint TherapeuticsNASDAQ:CKPTReneo PharmaceuticalsNASDAQ:RPHMView All Competitors TYME Stock Analysis - Frequently Asked Questions How were Tyme Technologies' earnings last quarter? Tyme Technologies, Inc. (NASDAQ:TYME) issued its quarterly earnings results on Monday, November, 8th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.03. What other stocks do shareholders of Tyme Technologies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Tyme Technologies investors own include Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), TherapeuticsMD (TXMD), Vaxart (VXRT), Allena Pharmaceuticals (ALNA), OpGen (OPGN), Selecta Biosciences (SELB), MEI Pharma (MEIP), Pfizer (PFE) and SCYNEXIS (SCYX). This page (NASDAQ:TYME) was last updated on 4/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyme Technologies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
